3rv8: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Structure of a M. tuberculosis Salicylate Synthase, MbtI, in Complex with an Inhibitor with Cyclopropyl R-Group==
==Structure of a M. tuberculosis Salicylate Synthase, MbtI, in Complex with an Inhibitor with Cyclopropyl R-Group==
<StructureSection load='3rv8' size='340' side='right' caption='[[3rv8]], [[Resolution|resolution]] 2.29&Aring;' scene=''>
<StructureSection load='3rv8' size='340' side='right'caption='[[3rv8]], [[Resolution|resolution]] 2.29&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[3rv8]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Mycobacterium_tuberculosis Mycobacterium tuberculosis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3RV8 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3RV8 FirstGlance]. <br>
<table><tr><td colspan='2'>[[3rv8]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Mycobacterium_tuberculosis Mycobacterium tuberculosis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3RV8 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3RV8 FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=RVC:3-{[(Z)-1-CARBOXY-2-CYCLOPROPYLETHENYL]OXY}-2-HYDROXYBENZOIC+ACID'>RVC</scene>, <scene name='pdbligand=VCE:3-{[(E)-1-CARBOXY-2-CYCLOPROPYLETHENYL]OXY}-2-HYDROXYBENZOIC+ACID'>VCE</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.29&#8491;</td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3rv6|3rv6]], [[3rv7|3rv7]], [[3rv9|3rv9]]</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=RVC:3-{[(Z)-1-CARBOXY-2-CYCLOPROPYLETHENYL]OXY}-2-HYDROXYBENZOIC+ACID'>RVC</scene>, <scene name='pdbligand=VCE:3-{[(E)-1-CARBOXY-2-CYCLOPROPYLETHENYL]OXY}-2-HYDROXYBENZOIC+ACID'>VCE</scene></td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Rv2386c ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=1773 Mycobacterium tuberculosis])</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3rv8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3rv8 OCA], [https://pdbe.org/3rv8 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3rv8 RCSB], [https://www.ebi.ac.uk/pdbsum/3rv8 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3rv8 ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3rv8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3rv8 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3rv8 RCSB], [http://www.ebi.ac.uk/pdbsum/3rv8 PDBsum]</span></td></tr>
</table>
</table>
<div style="background-color:#fffaf0;">
== Function ==
== Publication Abstract from PubMed ==
[https://www.uniprot.org/uniprot/MBTI_MYCTU MBTI_MYCTU] Mediates the production of salicylate from chorismate via an isochorismate intermediate. Presents both isochorismate synthase and isochorismate-pyruvate lyase activities. Salycilate is the starter unit in the production of the virulence-conferring salicylate-based siderophore mycobactin.<ref>PMID:16923875</ref>  
MbtI is the salicylate synthase that catalyzes the first committed step in the synthesis of the iron chelating compound mycobactin in Mycobacterium tuberculosis. We previously developed a series of aromatic inhibitors against MbtI based on the reaction intermediate for this enzyme, isochorismate. The most potent of these inhibitors had hydrophobic substituents, ranging in size from a methyl to a phenyl group, appended to the terminal alkene of the enolpyruvyl group. These compounds exhibited low micromolar inhibition constants against MbtI and were at least an order of magnitude more potent than the parental compound for the series, which carries a native enolpyruvyl group. In this study, we sought to understand how the substituted enolpyruvyl group confers greater potency, by determining cocrystal structures of MbtI with six inhibitors from the series. A switch in binding mode at the MbtI active site is observed for inhibitors carrying a substituted enolpyruvyl group, relative to the parental compound. Computational studies suggest that the change in binding mode, and higher potency, is due to the effect of the substituents on the conformational landscape of the core inhibitor structure. The crystal structures and fluorescence-based thermal shift assays indicate that substituents larger than a methyl group are accommodated in the MbtI active site through significant but localized flexibility in the peptide backbone. These findings have implications for the design of improved inhibitors of MbtI, as well as other chorismate-utilizing enzymes from this family.
 
Implications of Binding Mode and Active Site Flexibility for Inhibitor Potency against the Salicylate Synthase from Mycobacterium tuberculosis.,Chi G, Manos-Turvey A, O'Connor PD, Johnston JM, Evans GL, Baker EN, Payne RJ, Lott JS, Bulloch EM Biochemistry. 2012 Jun 7. PMID:22607697<ref>PMID:22607697</ref>
 
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>


==See Also==
==See Also==
Line 23: Line 17:
__TOC__
__TOC__
</StructureSection>
</StructureSection>
[[Category: Large Structures]]
[[Category: Mycobacterium tuberculosis]]
[[Category: Mycobacterium tuberculosis]]
[[Category: Bulloch, E M.M]]
[[Category: Bulloch EMM]]
[[Category: Chi, G]]
[[Category: Chi G]]
[[Category: Lott, J S]]
[[Category: Lott JS]]
[[Category: Manos-Turvey, A]]
[[Category: Manos-Turvey A]]
[[Category: Payne, R J]]
[[Category: Payne RJ]]
[[Category: Structural genomic]]
[[Category: Chorismate binding]]
[[Category: Isomerase-isomerase inhibitor complex]]
[[Category: Salicylate synthase]]
[[Category: Tbsgc]]

Latest revision as of 11:36, 20 March 2024

Structure of a M. tuberculosis Salicylate Synthase, MbtI, in Complex with an Inhibitor with Cyclopropyl R-GroupStructure of a M. tuberculosis Salicylate Synthase, MbtI, in Complex with an Inhibitor with Cyclopropyl R-Group

Structural highlights

3rv8 is a 4 chain structure with sequence from Mycobacterium tuberculosis. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:X-ray diffraction, Resolution 2.29Å
Ligands:,
Resources:FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

MBTI_MYCTU Mediates the production of salicylate from chorismate via an isochorismate intermediate. Presents both isochorismate synthase and isochorismate-pyruvate lyase activities. Salycilate is the starter unit in the production of the virulence-conferring salicylate-based siderophore mycobactin.[1]

See Also

References

  1. Harrison AJ, Yu M, Gardenborg T, Middleditch M, Ramsay RJ, Baker EN, Lott JS. The structure of MbtI from Mycobacterium tuberculosis, the first enzyme in the biosynthesis of the siderophore mycobactin, reveals it to be a salicylate synthase. J Bacteriol. 2006 Sep;188(17):6081-91. PMID:16923875 doi:http://dx.doi.org/188/17/6081

3rv8, resolution 2.29Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA